Answers are grounded in this paper and cite their sources.
Background: Roux-en-Y gastric bypass (RYGB) is currently the most effective treatment of morbid obesity in man. In rodents, RYGB leads to a number of morphological changes in the intestine. However, little is known about the effect of RYGB surgery on intestinal morphology and enteroendocrine L-cells in larger animals and man. Here we performed RYGB surgery in obese Gttingen minipigs, to assess whether the intervention is associated with changes in intestinal volume, L-cell number and plasma levels of glucose, insulin, glucagon-like peptide-1 (GLP-1) and leptin.
No takes yet. Share an insight, caveat, or question.
Barkholt et al. (2015) studied this question.
Synapse has enriched 6 related papers. Consider them for comparative context: